GlassScriptPhysician profile
Jeffrey Wayne Thornton
NPI 1033163266
$5,632.42
in general payments reported to CMS, 2019-2025
45 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $345 · 2021: $790 · 2022: $806 · 2023: $801 · 2024: $900 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.58 | 2020-2025 | Ubrelvy, Botox, Qulipta |
| Novartis Pharmaceuticals Corporation | $571.98 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $535.49 | 2019-2020 | |
| Ucb, INC. | $360.27 | 2019-2025 | Fintepla, Nayzilam, Zilbrysq |
| Lilly USA, LLC | $330.42 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Argenx US, INC. | $238.15 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $230.82 | 2021-2025 | Xcopri |
| Biogen, INC. | $220.27 | 2019-2025 | Tysabri, Vumerity |
| Amgen INC. | $209.97 | 2019-2024 | Repatha, Otezla, Uplizna |
| Amneal Pharmaceuticals LLC | $161.74 | 2022-2025 | Rytary, Crexont |
| Pfizer INC. | $148.66 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $138.45 | 2019-2025 | Ajovy |
| Genentech USA, INC. | $134.80 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $122.24 | 2021 | |
| Alexion Pharmaceuticals, INC. | $100.05 | 2019-2024 | Ultomiris, Soliris |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.